M
Manoj M. Lalu
Researcher at Ottawa Hospital Research Institute
Publications - 196
Citations - 29529
Manoj M. Lalu is an academic researcher from Ottawa Hospital Research Institute. The author has contributed to research in topics: Medicine & Clinical trial. The author has an hindex of 35, co-authored 149 publications receiving 5799 citations. Previous affiliations of Manoj M. Lalu include University of Ottawa & University of Alberta.
Papers
More filters
Journal ArticleDOI
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page,Joanne E. McKenzie,Patrick M.M. Bossuyt,Isabelle Boutron,Tammy Hoffmann,Cynthia D. Mulrow,Larissa Shamseer,Jennifer Tetzlaff,Elie A. Akl,Sue E. Brennan,Roger Chou,Julie Glanville,Jeremy M. Grimshaw,Asbjørn Hróbjartsson,Manoj M. Lalu,Tianjing Li,Elizabeth Loder,Evan Mayo-Wilson,Steve McDonald,Luke A McGuinness,Lesley A. Stewart,James Thomas,Andrea C. Tricco,Vivian Welch,Penny Whiting,David Moher +25 more
TL;DR: The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement as discussed by the authors was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found.
Journal ArticleDOI
PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.
Matthew J. Page,David Moher,Patrick M.M. Bossuyt,Isabelle Boutron,Tammy Hoffmann,Cynthia D. Mulrow,Larissa Shamseer,Jennifer Tetzlaff,Elie A. Akl,Sue E. Brennan,Roger Chou,Julie Glanville,Jeremy M. Grimshaw,Asbjørn Hróbjartsson,Manoj M. Lalu,Tianjing Li,Elizabeth Loder,Evan Mayo-Wilson,Steve McDonald,Luke A McGuinness,Lesley A. Stewart,James Thomas,Andrea C. Tricco,Vivian Welch,Penny Whiting,Joanne E. McKenzie +25 more
TL;DR: The preferred reporting items for systematic reviews and meta-analyses (PRISMA 2020) as mentioned in this paper was developed to facilitate transparent and complete reporting of systematic reviews, and has been updated to reflect recent advances in systematic review methodology and terminology.
Journal ArticleDOI
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page,Joanne E. McKenzie,Patrick M.M. Bossuyt,Isabelle Boutron,Tammy Hoffmann,Cynthia D. Mulrow,Larissa Shamseer,Jennifer Tetzlaff,Elie A. Akl,Sue E. Brennan,Roger Chou,Julie Glanville,Jeremy M. Grimshaw,Asbjørn Hróbjartsson,Manoj M. Lalu,Tianjing Li,Elizabeth Loder,Evan Mayo-Wilson,Steve McDonald,Luke A McGuinness,Lesley A. Stewart,James Thomas,Andrea C. Tricco,Vivian Welch,Penny Whiting,David Moher +25 more
TL;DR: The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement as discussed by the authors was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found.
Journal ArticleDOI
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.
Matthew J. Page,Joanne E. McKenzie,Patrick M.M. Bossuyt,Isabelle Boutron,Tammy Hoffmann,Cynthia D. Mulrow,Larissa Shamseer,Jennifer Tetzlaff,Elie A. Akl,Sue E. Brennan,Roger Chou,Julie Glanville,Jeremy M. Grimshaw,Asbjørn Hróbjartsson,Manoj M. Lalu,Tianjing Li,Elizabeth Loder,Evan Mayo-Wilson,Steve McDonald,Luke A McGuinness,Lesley A. Stewart,James Thomas,Andrea C. Tricco,Vivian Welch,Penny Whiting,David Moher +25 more
TL;DR: The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement as discussed by the authors was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found.
Journal ArticleDOI
Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials
Manoj M. Lalu,Lauralyn McIntyre,Lauralyn McIntyre,Christina Pugliese,Dean Fergusson,Brent W. Winston,John C. Marshall,John Granton,Duncan J. Stewart,Duncan J. Stewart +9 more
TL;DR: Based on the current clinical trials, MSC therapy appears safe, however, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs.